Exact Sciences Slides as Institutional Sales Clash with Bullish Bets Traders 460th in Volume Amid Analyst Downgrades and $21B Buyout Whispers

Market Snapshot

On March 10, 2026, Exact Sciences (NASDAQ: EXAS) closed with a 0.33% decline, trading at a volume of $0.27 billion, which ranked it 460th in daily trading activity. The stock opened at $103.71, slightly above its 50-day moving average of $102.69 but significantly above its 200-day average of $82.52. Despite the modest drop, the stock remains near its 52-week high of $103.75, reflecting a broader upward trend since its 52-week low of $38.81. The company’s market capitalization stands at $19.8 billion, with a forward P/E ratio of -94.28 and a beta of 1.41, indicating high volatility relative to the broader market.

Key Drivers

The stock’s recent performance was influenced by a mix of institutional investor activity, analyst sentiment shifts, and underlying financial results. A key factor was the reduction in holdings by Blair William & Co. IL, which cut its position in EXAS by 14.9% during the third quarter, selling 24,493 shares to retain 139,494 shares valued at $7.63 million. This move contrasted with increased stakes from other investors, including OFI Invest Asset Management (up 241.2%) and China Universal Asset Management (up 463.0%), suggesting divergent views on the company’s near-term prospects.

Analyst actions further complicated the outlook. TD Cowen downgraded EXAS from “Buy” to “Hold,” while William Blair reduced its rating to “Market Perform” from “Outperform.” Mizuho and Evercore maintained “In-Line” or “Neutral” ratings, with price targets clustered around $105. The consensus “Reduce” rating on MarketBeat underscored cautious optimism, though analysts projected a fiscal year EPS of -$0.58, reflecting ongoing profitability challenges.

Exact Sciences’ Q4 2025 earnings report added pressure, as the firm posted a $0.21 loss per share—$0.29 below estimates—despite a 23.1% year-over-year revenue increase. The company’s negative net margin of 6.40% and a return on equity of 0.53% highlighted structural inefficiencies. However, the revenue growth signaled resilience in demand for its flagship Cologuard test and expanding diagnostic portfolio.

The stock’s technical indicators also played a role. While the RSI of 45.82 indicated a neutral position, the MACD (0.37) lagging below its signal line (0.47) raised short-term bearish concerns. Additionally, the absence of a dividend and a payout ratio of 0.00% reinforced the company’s focus on reinvestment over shareholder returns, aligning with its growth-at-all-costs strategy.

A notable development was the rumored $21 billion acquisition offer from Abbott, which, if confirmed, could trigger a sharp revaluation. However, no official announcement was included in the provided data, leaving the stock’s trajectory dependent on regulatory and strategic outcomes.

Strategic Context

Exact Sciences’ core business remains anchored in its Cologuard test, a market leader in noninvasive colorectal cancer screening. The company’s partnerships with institutions like the Mayo Clinic and its pipeline of multi-cancer detection tests position it to benefit from the $100 billion global diagnostics market. However, its high valuation metrics—such as a P/E/G ratio of 2.36 and a debt-to-equity ratio of 0.97—reflect investor expectations for rapid revenue growth to justify current multiples.

The mixed institutional investor activity and analyst ratings underscore uncertainty around the company’s ability to sustain profitability while scaling operations. While increased stakes from OFI and China Universal suggest confidence in long-term innovation, the sell-off by Blair William & Co. and downgrades from key analysts indicate skepticism about short-term execution risks.

In conclusion, Exact Sciences’ stock remains a high-volatility play, driven by its pivotal role in cancer diagnostics and strategic initiatives. Investors must balance optimism around revenue growth and product expansion with caution over earnings pressures and analyst skepticism. The potential for an acquisition or regulatory breakthrough could act as a catalyst, but the stock’s path forward hinges on navigating these competing dynamics.